David Spetzler

9.5k total citations · 2 hit papers
84 papers, 1.7k citations indexed

About

David Spetzler is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, David Spetzler has authored 84 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 37 papers in Cancer Research and 33 papers in Molecular Biology. Recurrent topics in David Spetzler's work include Cancer Genomics and Diagnostics (30 papers), Glioma Diagnosis and Treatment (13 papers) and Genetic factors in colorectal cancer (12 papers). David Spetzler is often cited by papers focused on Cancer Genomics and Diagnostics (30 papers), Glioma Diagnosis and Treatment (13 papers) and Genetic factors in colorectal cancer (12 papers). David Spetzler collaborates with scholars based in United States, Germany and Japan. David Spetzler's co-authors include Zoran Gatalica, John L. Marshall, Wayne D. Frasch, Ari M. Vanderwalde, Nianqing Xiao, Joanne Xiu, Amy B. Heimberger, Tassilo Hornung, Robert Ishmukhametov and Shouhao Zhou and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

In The Last Decade

David Spetzler

75 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients

2018 333 citations Ari M. Vanderwalde, David Spetzler et al. Cancer Medicine profile →
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

2017 308 citations Tiffany R. Hodges, Joanne Xiu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Spetzler United States	19	755	616	429	410	365	84	1.7k
Melanie M. Frigault United States	16	524 0.7×	716 1.2×	235 0.5×	326 0.8×	768 2.1×	63	1.6k
Ellen C. Obermann Switzerland	26	1.1k 1.4×	871 1.4×	466 1.1×	141 0.3×	368 1.0×	76	2.8k
Christopher E. Pelloski United States	17	532 0.7×	1.1k 1.8×	540 1.3×	847 2.1×	439 1.2×	35	2.2k
Matthias Holdhoff United States	27	604 0.8×	596 1.0×	267 0.6×	821 2.0×	348 1.0×	111	2.1k
Charles N. Pegram United States	27	830 1.1×	855 1.4×	199 0.5×	611 1.5×	321 0.9×	46	2.3k
Gamal Akabani United States	29	669 0.9×	533 0.9×	165 0.4×	472 1.2×	726 2.0×	67	3.1k
Shuchun Zhao United States	20	792 1.0×	954 1.5×	239 0.6×	219 0.5×	108 0.3×	48	2.1k
Pierre-Yves Dietrich Switzerland	13	624 0.8×	942 1.5×	569 1.3×	1.5k 3.6×	536 1.5×	14	2.5k
Nduka Amankulor United States	21	641 0.8×	791 1.3×	510 1.2×	943 2.3×	339 0.9×	56	2.4k
Sara Malatesta Italy	14	739 1.0×	1.0k 1.6×	1.0k 2.4×	236 0.6×	823 2.3×	18	1.9k

Countries citing papers authored by David Spetzler

Since Specialization

Citations

This map shows the geographic impact of David Spetzler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Spetzler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Spetzler more than expected).

Fields of papers citing papers by David Spetzler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Spetzler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Spetzler. The network helps show where David Spetzler may publish in the future.

Co-authorship network of co-authors of David Spetzler

This figure shows the co-authorship network connecting the top 25 collaborators of David Spetzler. A scholar is included among the top collaborators of David Spetzler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Spetzler. David Spetzler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ribeiro, Jennifer R., Todd Maney, Stephanie Rock, et al.. (2025). GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor Profiling. Cancer Research Communications. 5(9). 1477–1489. 1 indexed citations

Sledge, George W., Takayuki Yoshino, Jennifer R. Ribeiro, et al.. (2025). Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals. Nature Communications. 16(1). 2646–2646. 4 indexed citations

Alvero, Ayesha B., Sharon Wu, Alex Farrell, et al.. (2025). Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis. Gynecologic Oncology. 194. 71–79. 2 indexed citations

Cheng, Yating, Ming Chen, Joanne Xiu, et al.. (2025). Synergistic H&E and IHC image analysis by AI predicts cancer biomarkers and survival outcomes in colorectal and breast cancer. Communications Medicine. 5(1). 328–328.

Espinoza, Magdalena, Andrew Elliott, Joanne Xiu, et al.. (2024). Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers. Nature Cancer. 5(7). 1121–1129. 11 indexed citations

Malla, Midhun, Sachin Kumar Deshmukh, Sharon Wu, et al.. (2024). Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer. Cancer Gene Therapy. 31(10). 1547–1558. 6 indexed citations

El‐Deiry, Wafik S., Emil Lou, Vivek Subbiah, et al.. (2024). Therapeutic insights for the aggressive subset of high-grade gliomas (HGG) driven by chromosome 1q32 MDM4-containing amplicon and unmethylated MGMT.. Journal of Clinical Oncology. 42(16_suppl). 2080–2080. 1 indexed citations

Darabi, Sourat, Joanne Xiu, Santosh Kesari, et al.. (2023). Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target. Medical Oncology. 40(7). 197–197. 10 indexed citations

Nagasaka, Misako, Yasmine Baca, Joanne Xiu, et al.. (2023). Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset. Translational Oncology. 36. 101744–101744. 13 indexed citations

10.

Darabi, Sourat, Joanne Xiu, Benedito A. Carneiro, et al.. (2022). BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents. Medicina. 58(12). 1818–1818. 10 indexed citations

11.

Evans, Elizabeth, Jim Abraham, Jian Zhang, et al.. (2022). Whole exome sequencing provides loss of heterozygosity (LoH) data comparable to that of whole genome sequencing (171). Gynecologic Oncology. 166. S100–S100. 4 indexed citations

12.

Elliott, Andrew, Jian Zhang, Qing Zhang, et al.. (2021). Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types. Journal of Molecular Diagnostics. 23(12). 1761–1773. 4 indexed citations

13.

Abraham, Jim, Daniel Magee, Chiara Cremolini, et al.. (2020). Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clinical Cancer Research. 27(4). 1174–1183. 35 indexed citations

14.

Vranić, Semir, Phillip Stafford, Juan Palazzo, et al.. (2020). Molecular Profiling of the Metaplastic Spindle Cell Carcinoma of the Breast Reveals Potentially Targetable Biomarkers. Clinical Breast Cancer. 20(4). 326–331.e1. 28 indexed citations

15.

Ou, Sai‐Hong Ignatius, Joanne Xiu, Misako Nagasaka, et al.. (2020). Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing. JTO Clinical and Research Reports. 2(2). 100132–100132. 6 indexed citations

16.

Gatalica, Zoran, Semir Vranić, Phillip Stafford, et al.. (2019). Spindle cell carcinoma of the breast: Rare cancer with potentially targetable biomarkers. Annals of Oncology. 30. iii19–iii19. 1 indexed citations

17.

Pannu, Vaishali, Matthew Rosenow, Daniel Magee, et al.. (2019). Translocation of a Cell Surface Spliceosomal Complex Induces Alternative Splicing Events and Lymphoma Cell Necrosis. Cell chemical biology. 26(5). 756–764.e6. 5 indexed citations

18.

Vanderwalde, Ari M., David Spetzler, Nianqing Xiao, Zoran Gatalica, & John L. Marshall. (2018). Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients. Cancer Medicine. 7(3). 746–756. 333 indexed citations breakdown →

19.

Everson, Richard G., Yuuri Hashimoto, Jacob Freeman, et al.. (2018). Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. Journal of Neuro-Oncology. 139(2). 469–478. 18 indexed citations

20.

Spetzler, David, et al.. (2008). Single-molecule detection of DNA via sequence-specific links between F1-ATPase motors and gold nanorod sensors. Lab on a Chip. 8(3). 415–415. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact